Growth Metrics

Capricor Therapeutics (CAPR) Net Income towards Common Stockholders: 2011-2024

Historic Net Income towards Common Stockholders for Capricor Therapeutics (CAPR) over the last 14 years, with Dec 2024 value amounting to -$40.4 million.

  • Capricor Therapeutics' Net Income towards Common Stockholders fell 95.68% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$68.4 million, marking a year-over-year decrease of 100.10%. This contributed to the annual value of -$40.4 million for FY2024, which is 80.60% down from last year.
  • According to the latest figures from FY2024, Capricor Therapeutics' Net Income towards Common Stockholders is -$40.4 million, which was down 80.60% from -$22.3 million recorded in FY2023.
  • Over the past 5 years, Capricor Therapeutics' Net Income towards Common Stockholders peaked at -$13.7 million during FY2020, and registered a low of -$40.4 million during FY2024.
  • Its 3-year average for Net Income towards Common Stockholders is -$30.6 million, with a median of -$29.2 million in 2022.
  • As far as peak fluctuations go, Capricor Therapeutics' Net Income towards Common Stockholders increased by 23.40% in 2023, and later crashed by 80.60% in 2024.
  • Yearly analysis of 5 years shows Capricor Therapeutics' Net Income towards Common Stockholders stood at -$13.7 million in 2020, then crashed by 52.90% to -$20.9 million in 2021, then tumbled by 39.72% to -$29.2 million in 2022, then grew by 23.40% to -$22.3 million in 2023, then plummeted by 80.60% to -$40.4 million in 2024.